EUCTR2021-004149-19-IT招募中1 期
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER - not available
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Age >=18 years
- •Body weight >=30 kgWhole-body positron emission tomography/computed tomography scan (PET/CT) performed prior and within 42 days of the first dose of cCRT or sCRT
- •Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology (Version 8, American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system (Amin et al. 2017).
- •Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT)
- •The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (± 10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique
- •No disease progression during or following platinum-based cCRT or sCRT
- •Life expectancy = 12 weeks
- •Documented tumor PD-L1 status
- •Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2
- •Adequate hematologic and end-organ function
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period and for at least 90 days after the final dose of alectinib or durvalumab (Cohort A1 only)
- •For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period, and for at least 35 days after the final dose of entrectinib, or 90 days after the final dose of durvalumab (Cohort A2 only)
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period, and for at least 14 days after the final dose of pralsetinib, or at least 90 days after the final dose of durvalumab (Cohort A3 only)
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm during the treatment period and for least 90 days after the final dose of alectinib or durvalumab (Cohort A1 only)
- •For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom plus an additional contraception method, and agreement to refrain from donating sperms, during the treatment period and for at least 3 months after the final dose of entrectinib or final dose of durvalumab Cohort A2 only)
- •For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, during the treatment period and for at least 7 days after the final dose of pralsetinib and at least 90 days after the final dose of durvalumab (Cohort A3 only)
- •Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules (Cohort A2 only)
- •Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen
- •Documented ALK fusion positivity (Cohort A1 only)
- •Documented ROS1 fusion positivity (Cohort A2 only)
- •Documented RET fusion positivity (Cohort A3 only
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 yea
排除标准
- •Any history of previous NSCLC and/or any history of prior treatment for NSCLC
- •Any evidence of Stage IV disease
- •If pleural effusion is present the following criteria must be met to exclude malignant involvement (T4 disease):
- •When pleural fluid is visible on both the computed tomography scan and chest X-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative.
- •Patients with exudative pleural effusions are excluded regardless of cytology.
- •Patients with effusions that are minimal (i.e., not visible on chest X-ray) that are too small to safely tap are eligible
- •NSCLC known to have one or more of the following ALK point mutations, as identified by site local testing or Sponsor central testing: I1171X (where X is any other amino acid), V1180L, G1202R (Cohort A1).
- •NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing
- •Liver disease
- •Positive hepatitis B surface antigen test at screening
- •Patients known to be positive for hepatitis C virus antibody
- •HIV infection, patients are excluded if HIV is not adequately controlled (specific criteria apply).
- •Known active tuberculosis
- •Presence of clinically symptomatic interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis
- •Grade = 2 pneumonitis from prior cCRT or sCRT
- •Symptomatic bradycardia (Cohort A1,A2)
- •Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
- •Left ventricular ejection fraction less than or equal to 50% observed during the screening for the study (Cohort A2)
- •Any gastrointestinal (GI) disorder that may affect absorption of oral medications
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
- •Active or history of autoimmune disease or immune deficiency
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan
- •History of malignancy other than NSCLC within 5 years prior to screening
- •Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
- •Major surgical procedure, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
- •Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
- •Treatment with systemic immunostimulatory agents
- •Treatment with live, attenuated vaccine
- •Treatment with investigational therapy within 28 days prior to initiation of study treatment
- •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
- •Treatment with systemic immunosuppressive medication
- •Prior treatment with ALK inhibitors (Cohort A1)
- •Prior treatment with ROS1 inhibitors (Cohort A2)
- •Prior treatment with RET inhibitors (Cohort A3)
- •Prior treatment with CD137 agonists or immune checkpoint blockade therapies
- •Prior allogeneic stem cell or solid organ transplantation
- •History of hypersensitivity to alectinib, durvalumab, or any of their excipients (Cohort A1)
- •History of hypersensitivity to
研究者
相似试验
尚未招募
不适用
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCERNL-OMON53740Roche Nederland B.V.3
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial)Advanced or metastatic Non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000076-28-ITF. HOFFMANN - LA ROCHE LTD.660
招募中
2 期
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)CancerPACTR202211687583152Hoffmann La Roche682
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial)Advanced or metastatic Non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000076-28-BEF. Hoffmann-La Roche Ltd987
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial)EUCTR2017-000076-28-ESRoche Farma S.A (Soc.Unipersonal) que realiza el ensayo568